Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Dow
Harvard Business School
McKinsey
Johnson and Johnson

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR HALDOL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Haldol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000179 ↗ Agitation in Alzheimer's Disease Completed National Institute on Aging (NIA) Phase 3 1969-12-31 Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for patients at home very difficult. Trazodone and haldol are two of the most commonly prescribed drugs for agitation in AD patients. Behavior management, a non drug approach, has been effective in reducing signs of agitation. Researchers have yet to compare the effectiveness of drug versus non drug therapy to treat agitation in AD patients and determine which is the best treatment. The Alzheimer's Disease Cooperative Study, with funding from the National Institute on Aging, is conducting an agitation treatment program at 21 sites in 16 States. This study will assess which of the above treatments is most effective.
NCT00009217 ↗ Treatment of Behavioral Symptoms in Alzheimer's Disease Completed National Institute of Mental Health (NIMH) Phase 4 1999-01-01 The optimal strategy for the treatment of behavioral complications in patients with probable Alzheimer's disease (AD) remains unclear. The objective of this study is to evaluate the risk of relapse following discontinuation of haloperidol in patients with Alzheimer's disease (AD) with psychosis or agitation who respond to it. In Phase A of this study, AD outpatients with behavioral complications receive 20 weeks of open haloperidol treatment with an oral dose of 1-5 mg daily, titrated individually to achieve the optimal trade-off between efficacy and side effects. Responders to Phase A participate in Phase B, a 24-week continuation trial in which patients are randomized to continuation haloperidol or placebo. The primary outcome is the time to relapse of psychosis or behavioral disturbance.
NCT00009217 ↗ Treatment of Behavioral Symptoms in Alzheimer's Disease Completed New York State Psychiatric Institute Phase 4 1999-01-01 The optimal strategy for the treatment of behavioral complications in patients with probable Alzheimer's disease (AD) remains unclear. The objective of this study is to evaluate the risk of relapse following discontinuation of haloperidol in patients with Alzheimer's disease (AD) with psychosis or agitation who respond to it. In Phase A of this study, AD outpatients with behavioral complications receive 20 weeks of open haloperidol treatment with an oral dose of 1-5 mg daily, titrated individually to achieve the optimal trade-off between efficacy and side effects. Responders to Phase A participate in Phase B, a 24-week continuation trial in which patients are randomized to continuation haloperidol or placebo. The primary outcome is the time to relapse of psychosis or behavioral disturbance.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Haldol

Condition Name

Condition Name for Haldol
Intervention Trials
Delirium 14
Schizophrenia 7
Psychosis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Haldol
Intervention Trials
Delirium 17
Psychomotor Agitation 9
Schizophrenia 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Haldol

Trials by Country

Trials by Country for Haldol
Location Trials
United States 62
Netherlands 8
Canada 5
China 4
Iran, Islamic Republic of 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Haldol
Location Trials
Texas 6
California 5
Ohio 5
New York 5
Michigan 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Haldol

Clinical Trial Phase

Clinical Trial Phase for Haldol
Clinical Trial Phase Trials
Phase 4 20
Phase 3 10
Phase 2/Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Haldol
Clinical Trial Phase Trials
Completed 28
Terminated 12
Unknown status 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Haldol

Sponsor Name

Sponsor Name for Haldol
Sponsor Trials
National Cancer Institute (NCI) 4
National Institute on Aging (NIA) 3
National Institute of Mental Health (NIMH) 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Haldol
Sponsor Trials
Other 61
NIH 13
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Boehringer Ingelheim
Medtronic
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.